Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radium Ra 223 dichloride · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Radium Ra 223 dichloride | EXPERIMENTAL | Radium Ra 223 dichloride (Xofigo, BAY88-8223) |
| Name | Type | Description |
|---|---|---|
| Radium Ra 223 dichloride (Xofigo, BAY88-8223) | DRUG | 50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles |
| paclitaxel | DRUG | 90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1 |
Inclusion Criteria: * Male or female patients ≥ 18 years of age * Subjects diagnosed with histologically or cytologically confirmed malignant solid tumors and at least two according bone lesions. A standard of practice bone scan for the documentation of at least 2 bone lesions can be used as long a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Radium Ra 223 dichloride is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be cancerous. It is being evaluated in oncology for its potential to target bone lesions associated with cancer. The drug is currently in Phase 1 clinical development.
Radium Ra 223 dichloride is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with cancer and bone lesions.
Radium Ra 223 dichloride is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness. The drug is being studied in patients with neoplasms and bone diseases.
Radium Ra 223 dichloride has been studied in one clinical trial with the identifier NCT02442063. This was a Phase 1b study that combined Radium Ra 223 dichloride with paclitaxel in cancer subjects with bone lesions. The trial was completed and enrolled 15 participants across Finland, Israel, and the United Kingdom.
Radium Ra 223 dichloride is a form of radium-223, a radioactive isotope. The drug is designed to deliver radiation to bone lesions, which are areas of abnormal bone growth often associated with cancer. It is being investigated for its potential to treat neoplasms, particularly those affecting the bones.